Misonix (MSON) – Company Press Releases
-
Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus
-
BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration
-
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Sanderson Farms, Misonix, and Steadfast Apartment REIT on behalf of Stockholders and Encourages Investors to C
-
Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results
-
MISONIX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MSON and Encourages Investors to Contact the Firm
-
Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix
-
Misonix Reports Preliminary Fiscal 2021 Fourth Quarter and Full Year Revenue Results
-
Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance
-
Misonix Appoints Patrick J. Beyer to Board of Directors
-
Misonix to Participate in Upcoming May and June Virtual Investor Conferences
-
Misonix Reports Fiscal 2021 Third Quarter Financial Results
-
Misonix to Report Fiscal 2021 Third Quarter Financial Results and Host Conference Call and Webcast on May 6
-
Misonix Expands Ultrasonic Technology Capabilities to Address the Orthoplastics Market
-
Misonix Receives Health Canada Approval for neXus
-
Misonix to Participate in Upcoming March Investor Conferences
-
Misonix to Participate at Upcoming Investor Conferences
-
Misonix Reports Fiscal 2021 Second Quarter Financial Results
-
Misonix to Report Fiscal 2021 Second Quarter Financial Results and Host Conference Call and Webcast on February 4
-
Misonix to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives
-
Misonix to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Misonix to Participate at Upcoming Craig-Hallum and Canaccord Genuity Investor Conferences
-
Misonix Fiscal 2021 First Quarter Revenue Rises 59% to $17.7 Million
-
Misonix to Report Fiscal 2021 First Quarter Financial Results and Host Conference Call and Webcast on November 5
-
Misonix Reports Preliminary Fiscal 2021 First Quarter Revenue of Approximately $17.7 Million
-
Misonix Enters Into Exclusive Supply and Distribution Agreement With Gunze Limited for TheraGenesis® Bilayer Wound Matrix
-
Misonix to Present at the Cantor Virtual Global Healthcare Conference
-
Misonix Reports Fourth Quarter and Fiscal Year 2020 Results
-
Misonix to Report Fiscal 2020 Fourth Quarter Financial Results and Host Conference Call and Webcast on September 3
-
Misonix to Present at the 40th Annual Canaccord Genuity Growth Conference
-
Misonix Reports Preliminary Fiscal 2020 Fourth Quarter Revenue of Approximately $13.5 Million
-
Misonix to Present at the 17th Annual Craig Hallum Institutional Investor Conference On May 27
-
Misonix Fiscal 2020 Third Quarter Revenue Rises to $17.9 Million
-
Misonix to Report Fiscal 2020 Third Quarter Financial Results and Host Conference Call and Webcast on May 11
-
MISONIX REPORTS PRELIMINARY FISCAL 2020 THIRD QUARTER REVENUE OF APPROXIMATELY $17.9 MILLION
-
Misonix to Present at the 40th Annual Cowen Healthcare Conference on March 2
-
Misonix Reports Record Quarterly Revenue of $19.7 Million for Fiscal 2020 Second Quarter
-
Misonix Reports Record Quarterly Revenue of $19.7 Million for Fiscal 2020 Second Quarter
-
Misonix to Report Fiscal 2020 Second Quarter Financial Results And Host Conference Call and Webcast on February 5
-
Misonix Announces Pricing of Public Offering of Common Stock
-
Misonix Announces Public Offering of Common Stock
-
Misonix Reports Preliminary Fiscal 2020 Second Quarter Revenue of Approximately $19.7 Million
-
CryoLife and Misonix Enter Into Distribution Agreement for NeoPatch
-
Misonix to Present at 38th Annual J.P. Morgan Healthcare Conference
-
Misonix Announces Results of New Large Real-World Studies That Further Prove the Clinical Effectiveness of TheraSkin
-
Misonix Fiscal 2020 First Quarter Record Quarterly Product Revenue Of $11.1 Million
-
Misonix to Participate in Three Upcoming Investor Conferences
-
Misonix to Report Fiscal 2020 First Quarter Financial Results and Host Conference Call and Webcast on November 7
-
Misonix, Inc. Completes Acquisition of Regenerative Medical Company Solsys Medical
-
Misonix Reports Fourth Quarter and Fiscal Year 2019 Results
Back to MSON Stock Lookup